Literature DB >> 7156320

Familial antithrombin III deficiency.

J H Winter, A Fenech, W Ridley, B Bennett, A M Cumming, M Mackie, A S Douglas.   

Abstract

Antithrombin III is the major physiological inhibitor of the coagulation mechanism and a deficiency of this protein results in a marked predisposition to venous thromboembolic disease. Three Scottish families with a deficiency of this protein are described and other reported families are reviewed. The properties, functions and methods of assay of antithrombin III are outlined; the molecular abnormalities, inheritance, clinical and laboratory characteristics of antithrombin III deficiency are described, and the use of antithrombotic drugs and human antithrombin III concentrates in this deficiency is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7156320

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  6 in total

Review 1.  Neonatal haemostasis.

Authors:  B Gibson
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

2.  Evidence linking familial thrombosis with a defective antithrombin III gene in two British kindreds.

Authors:  S H Sacks; J M Old; S T Reeders; D J Weatherall; A S Douglas; J H Winter; C R Rizza
Journal:  J Med Genet       Date:  1988-01       Impact factor: 6.318

3.  Mesenteric venous thrombosis and antithrombin III deficiency.

Authors:  C Wilson; I D Walker; J F Davidson; C W Imrie
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

Review 4.  Anticoagulants in anaesthesia.

Authors:  P J Stow; F A Burrows
Journal:  Can J Anaesth       Date:  1987-11       Impact factor: 5.063

5.  Effect of danazol on the biochemical abnormality of inherited antithrombin III deficiency.

Authors:  A J Fairfax; R M Ibbotson
Journal:  Thorax       Date:  1985-09       Impact factor: 9.139

6.  Antithrombin III in patients admitted to intensive care units: a multicenter observational study.

Authors:  Andrea Messori; Franca Vacca; Monica Vaiani; Sabrina Trippoli
Journal:  Crit Care       Date:  2002-07-24       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.